Improving cancer therapy by identification of novel drug leads modulating transcription termination bridging molecular biology and therapeutic applications

forthcoming

Our value proposition is improving cancer therapy by identification of novel anti-cancer candidate drug leads modulating transcription termination, bridging molecular cancer biology and therapeutic applications. We have developed a methodology to directly measure alterations in transcription termination and successfully subjected it to miniaturization and automatization processes. We are applying for funding to validate a screening platform to identify small molecule inhibitors of transcription termination.